Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04261712 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)

A Phase 2 study of Acromegaly, sponsored by Crinetics Pharmaceuticals.

Active
Registry status
Phase 2
Development phase
43
Enrollment target
20
Study locations

NCT04261712 is a Phase 2 study of Acromegaly that is active but no longer recruiting, run by Crinetics Pharmaceuticals. The registered enrollment target is 43 participants, below the 98-participant average among 13 other Acromegaly trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04261712, a Phase 2 study of Acromegaly, is active but no longer recruiting, sponsored by Crinetics Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
43 participants
Enrollment target
20
Study locations

Study Summary

A phase 2, open label, long-term extension study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly.

Conditions Studied

Acromegaly

Interventions

  • DRUG Paltusotine

Study Locations (20)

Other

  • Crinetics Study Site - Rio de Janeiro
  • Crinetics Study Site - Rio de Janeiro
  • Crinetics Study Site - São Paulo
  • Crinetics Study Site - München
  • Crinetics Study Site - Athens
  • Crinetics Study Site 1 - Athens
  • Crinetics Study Site 2 - Athens
  • Crinetics Study Site - Thessaloniki
  • Crinetics Study Site - Budapest
  • Crinetics Study Site - Budapest
  • Crinetics Study Site - Pécs
  • Crinetics Study Site - Belgrade

Pennsylvania

  • Crinetics Study Site - Pittsburgh
  • Crinetics Study Site - Pittsburgh

California

  • Crinetics Study Site - Los Angeles

Illinois

  • Crinetics Study Site - Chicago

Massachusetts

  • Crinetics Study Site - Boston

Ohio

  • Crinetics Study Site - Columbus

Texas

  • Crinetics Study Site - Dallas

Paraná

  • Crinetics Study Site - Curitiba

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2020-01-29
Est. Completion 2028-03
Phase Phase 2

Sponsor

Crinetics Pharmaceuticals

16 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04261712

The ClinicalTrials.gov registry entry for NCT04261712 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 98-participant average among 13 other Acromegaly trials with a reported enrollment target (56% lower). The listed sponsor is Crinetics Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acromegaly appearing as the primary indexed condition, and to 1 intervention - of which Paltusotine is the first listed.

NCT04261712 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Pennsylvania, California.

Frequently Asked Questions

What is clinical trial NCT04261712 about?

NCT04261712 is a clinical study titled "A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)". A phase 2, open label, long-term extension study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly.

What is the current status of trial NCT04261712?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2020-01-29. Estimated completion is 2028-03.

What conditions does trial NCT04261712 study?

This clinical trial studies the following conditions: Acromegaly.

What interventions are being tested in trial NCT04261712?

The interventions under investigation include: Paltusotine (DRUG).

Who is sponsoring clinical trial NCT04261712?

This trial is sponsored by Crinetics Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04261712 being conducted?

This trial has 20 study locations across California, Illinois, Massachusetts, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acromegaly

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acromegaly

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.